We attended the 9th Annual SVB Leerink Global Healthcare Conference in New York from February 25 to 27, 2020, which hosted over 200 healthcare companies. As the spread of COVID-19 hit the markets this week, it was also the number one topic at the conference.
Implications for sales, supplies and products, as well as measures to control and contain the outbreak were widely debated. Everyone we talked to acknowledged that the virus outbreak has and will continue to have an impact but the important unanswered question is: how severe will it really be?
Did you know that R&D expenses of the 15 biggest pharma companies have increased by almost 50% since 2016 to USD 133 bn in 2021? And expenses will continue to increase. Roche alone for example will spend close to CHF 15 bn on R&D in 2022, 1 bn more than in 2021.
We attended the ESMO (European Society for Medical Oncology) annual oncology congress in Paris from Sept. 9-13. We came away very positive from the meeting, though two souls remain in our chest. On one side we see the amazing potential and the opportunities for new oncology therapies. On the other side complexity seems to potentially increase and so does competition in the space. But what to do as an investor? Find some proposals in our ESMO Thoughts from the Street.
September is traditionally one of the most important conference months, as second quarter reporting is largely complete and third quarter reporting has not yet started. We attended the 19th annual Goldman Sachs European Medtech and HC Services Conference 2022, held in London on September 7-8, again in a physical setting. While we remain mindful of all the sector headwinds, we left the conference more convinced that there are selectively attractive investment opportunities at current levels.